LENALIDOMIDE DRUG MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• In March 2023, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and NATCO Pharma Limited, a pharmaceutical company, announced the launch of additional strengths for the generic version of Revlimid (lenalidomide capsules) in the U.S., including 2.5 mg and 20 mg strengths
• In September 2022, Lotus Pharmaceutical, a multinational pharmaceutical company, announced the launch of lenalidomide Capsules (generic version of Revlimid) in the U.S. in strengths of 5mg, 10mg, 15mg, and 25mg
• In September 2022, Zydus Lifesciences Limited, a pharmaceutical company, announced that it had received the U.S. Food and Drug Administration (FDA) approval to market Lenalidomide Capsules, USP 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg. The company has gained final clearances for 5 mg, 10 mg, 15 mg, and 25 mg strengths, as well as preliminary approvals for 2.5 mg and 20 mg strength.
• In September 2022, Cipla Limited, an India-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had granted final approval for its Abbreviated New Drug Application (ANDA) for lenalidomide Capsule 5 mg, 10 mg, 15 mg, and 25 mg